|Articles|May 18, 2016
ERT Integrates Asthma Measurement Device
ERT announces it has successfully integrated the fractional exhaled Nitric Oxide (FeNO) measurement device by Aerocrine, a Circassia subsidiary, into it’s diagnostic platform for spirometry, ECG and home monitoring for centralized clinical trials.
Advertisement
ERT has integrated Circassia’s fractional exhaled Nitric Oxide (FeNO) measurement device into its MasterScope diagnostic platform, and is available for clinical trials. The device assists clinicians in evaluating and comparing allergic airway inflammations in patients with underlying asthma.
Read the full release
Advertisement
Related Content
Advertisement
Advertisement
Advertisement
Trending on Applied Clinical Trials Online
1
Quantifying the Net Financial Value of Deploying Risk-Based Quality Management
2
ACT Brief: RBQM Financial Value Quantified, Sponsor-Configurable AI Systems, and Basket Trials for Rare Pediatrics
3
ACT Brief: Enterprise Risk Management, Execution Architecture for AI, and Rare Pediatric Regulatory Support
4
AI-Driven Clinical Trial Recruitment and Design
5